Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pomalidomide · 1 trial · 1 indication
PFS is defined as the time in days from subject randomization to the date of the first documented progressive disease (PD) or death due to any cause, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| Arm 1 VenDex | EXPERIMENTAL | Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle. |
| Arm 2 PomDex | ACTIVE_COMPARATOR | Pomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle. |
| Name | Type | Description |
|---|---|---|
| Pomalidomide | DRUG | capsule, oral |
| Dexamethasone | DRUG | oral, locally available form |
| Venetoclax | DRUG | tablet; oral |
Inclusion Criteria: * Documented diagnosis of multiple myeloma (MM) based on standard International Myeloma Working Group (IMWG) criteria. * Measurable disease at screening as defined per protocol. * Has received at least 2 prior lines of therapy as described in the protocol. * Has had documented d...
Top 20 of 25 competitors
Pomalidomide is an investigational small molecule being studied for the treatment of Multiple Myeloma. It is currently in Phase 3 clinical development, specifically being evaluated in patients with t(11;14)-positive relapsed or refractory Multiple Myeloma. The drug is being developed by AbbVie Inc. (ABBV).
Pomalidomide targets the CRBN, DDB1, CUL4A, and RBX1 proteins, acting as an inhibitor of this target class. This mechanism is being studied in the context of Multiple Myeloma, where the drug is in Phase 3 clinical trials.
Pomalidomide is being developed by AbbVie Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ABBV. The company is conducting Phase 3 clinical trials of Pomalidomide for the treatment of Multiple Myeloma.
Pomalidomide is in Phase 3 clinical development. It is an investigational drug, not yet approved, and is being studied for the treatment of Multiple Myeloma. The ongoing Phase 3 trial is active but not recruiting participants.
Pomalidomide is being evaluated in a Phase 3 clinical trial with the identifier NCT03539744. This study compares Pomalidomide plus Dexamethasone (PomDex) against Venetoclax plus Dexamethasone (VenDex) in participants with t(11;14)-positive relapsed or refractory Multiple Myeloma. The trial has an enrollment of 265 participants.
Pomalidomide is the drug being studied, while PomDex refers to the combination regimen of Pomalidomide plus Dexamethasone. In the Phase 3 clinical trial NCT03539744, PomDex is the control arm being compared to Venetoclax plus Dexamethasone in patients with t(11;14)-positive relapsed or refractory Multiple Myeloma.